Bleeding Events Before vs After Lowering Departmental Platelet Transfusion Trigger
OBS-PLATE
Changes in Central Venous Catheterization Bleeding Events After Implementing a Lower Trigger For Platelet Transfusion - an Observational Study
1 other identifier
observational
927
1 country
1
Brief Summary
Central venous catheters are essential when administering treatment for hematological conditions. Many patients have a decreased platelet count which increases the risk for bleeding complications. Baarle et al. recently published a randomized controlled study where withholding prophylactic platelet transfusions before CVC placement in patients with a platelet count of 10,000 to 50,000 per cubic millimeter did not meet the predefined margin for non-inferiority for postprocedural bleeding events (PMID: 37224197). However, bleedings grade 2 (defined as bleeding that requires external compression) were included despite lacking clinical significance. The aim of the present study is to investigate whether lowering the preprocedural platelet transfusion trigger from 50x10\^9/L to 10x10\^9/L for insertions of central venous catheters remains safe with regards to postprocedural bleeding events of grade 3-4.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2024
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 17, 2023
CompletedFirst Posted
Study publicly available on registry
January 3, 2024
CompletedStudy Start
First participant enrolled
February 26, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 17, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
March 17, 2026
CompletedMay 1, 2026
April 1, 2026
2.1 years
December 17, 2023
April 27, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Incidence of bleeding events grade 3 and 4
Incidence of bleeding events grade 3 and 4 according to the National Cancer Institute Common Terminology criteria for Adverse events (CTCAE), version 5.0.
Up to 24 hours after insertion of a central venous catheter
Secondary Outcomes (3)
Incidence of bleeding events grade 2
Up to 24 hours after insertion of a central venous catheter
Number of patients receiving pre-procedural platelet transfusion Number of patients receiving pre-procedural platelet transfusion
From 24 hours before to 24 hours after insertion of a central venous catheter
Number of preprocedural units of platelet transfusions
From 24 hours before to 24 hours after insertion of a central venous catheter
Study Arms (2)
Before the change of the departmental pre-procedural platelet transfusion trigger for CVC placement
Patients ≥18 years of age admitted to a hematological ward at the current department, with an indication for CVC placement will be eligible for inclusion in the study
After the change of the departmental pre-procedural platelet transfusion trigger for CVC placement
Patients ≥18 years of age admitted to a hematological ward at the current department, with an indication for CVC placement will be eligible for inclusion in the study
Eligibility Criteria
Patients ≥18 years of age admitted to a hematological ward at the current department, with an indication for CVC placement, will be eligible for inclusion in the study.
You may qualify if:
- ≥ 18 years of age
- Indication for central venous catheter placement.
- Patients admitted to a hematological ward at the current department
You may not qualify if:
- Death within 24h after insertion of CVC.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Thomas Kanderlead
Study Sites (1)
Thomas Kander
Lund, Lunds Universitet, 22650, Sweden
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Thomas Kander, PhD
Region Skåne Sweden
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Target Duration
- 2 Days
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
December 17, 2023
First Posted
January 3, 2024
Study Start
February 26, 2024
Primary Completion
March 17, 2026
Study Completion
March 17, 2026
Last Updated
May 1, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, CSR
- Time Frame
- After the publication of the study up to 3 years after the publication of the study
- Access Criteria
- Researchers may submit requests through the specified channel, detailing the purpose and proposed analyses. Approved applicants will sign a data access agreement, ensuring responsible and transparent use of the data.
Upon reasonable request, de-identified individual participant data from this clinical trial will be shared to facilitate scientific collaboration.